SGLT-2抑制剂治疗糖尿病的研究进展

发布时间：2018-05-15 22:39

本文选题：糖尿病 + 钠-葡萄糖协同转运蛋白抑制剂　；参考：《山东医药》2017年46期

【摘要】：钠-葡萄糖协同转运蛋白2(SGLT-2)是肾小管内参与葡萄糖重吸收的关键蛋白分子,是近年来治疗糖尿病的新靶点。针对此靶点而研制的SGLT-2抑制剂是一种新型的口服降糖药物,其可通过减少肾脏对葡萄糖的重吸收,增加尿糖的排泄,达到降低血糖的作用。研究证实,SGLT-2抑制剂单药应用具有较好的血糖控制效果和代谢稳定性,与其他降糖药联合应用也可达到更好的血糖控制,同时还具有保护胰岛β细胞、降血压及降低体质量作用,从多方面发挥降糖作用。SGLT-2抑制剂的常见不良反应主要有低血糖、酮症酸中毒、泌尿生殖系统感染、急性胰腺炎等。
[Abstract]:Sodium-glucose co-transporter (SGLT-2) is a key protein molecule involved in glucose reabsorption in renal tubules and a new target for the treatment of diabetes in recent years. The SGLT-2 inhibitor developed for this target is a new oral hypoglycemic drug, which can reduce glucose excretion by reducing the reabsorption of glucose in the kidney. The results show that SGLT-2 inhibitor has better blood glucose control effect and metabolic stability, and can also achieve better blood glucose control in combination with other hypoglycemic drugs. It also has the effects of protecting islet 尾 cells, lowering blood pressure and reducing body mass. The common adverse effects of antidiabetic. SGLT-2 inhibitor were hypoglycemia, ketoacidosis, urinary and reproductive system infection, acute pancreatitis and so on.
【作者单位】：中国人民解放军海军军医大学;中国人民解放军海军军医大学附属长海医院;
【分类号】：R587.1

【相似文献】